Pfizer bags an FDA OK for PARP player talazoparib — now the hard part begins
Pfizer has picked up an approval for talazoparib, its PARP inhibitor for a genetically defined line of breast cancer. And now the pharma player can jump into a crowded market where AstraZeneca’s rival Lynparza is way out in front of the pack.
The Pfizer drug, which is hitting the market as Talzenna, figured prominently in Pfizer’s $14 billion Medivation buyout. The then Medivation CEO David Hung pitched talazoparib as a blockbuster-to-be as Sanofi stepped up first with an offer. Now Pfizer gets to find out just how much it can make as the fourth entry in the field, behind Clovis and Tesaro as well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.